secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001193125-23-268173
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Gene Therapies appoints Alison Long to Board; Kathleen Reape resigns
---------------------------------------------------------------------------

- Kathleen Reape resigns from Board effective Nov 1, 2023, per employer governance rules; no disagreement with company.
- Alison Long appointed as Class I director effective Nov 1, 2023, and chair of Clinical and Science Committee.
- Long also appointed to Compensation and Nominating & Corporate Governance Committees.
- Long receives initial stock option for 43,800 shares vesting over 36 months plus annual retainers ($35k director, extra committee fees).
- Long currently CMO of Flightpath Biosciences (consulting) and Clinical Lead of Enigma Biomedical Group; previously CMO at Anokion, Kaleido.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523268173/0001193125-23-268173-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523268173/d556180d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-268173

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer